FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

By /

Biogen Inc. and Sage Therapeutics, Inc. announced the U.S. Food and Drug Administration approved ZURZUVAE™ 50 mg for adults with postpartum depression.

Scroll to Top